Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. - Wikidata - wikimedia - TriplyDB

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

http://www.wikidata.org/entity/Q34299064

about

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.

P2860

Q36438924-546F4C05-8921-4896-917C-9CCB51BC8CEE Q37287648-E99B90D9-3F02-4264-88D5-B6492AC3627D Q37308807-0404FE19-C9C7-495B-850F-CD3D735E6A43 Q37358630-531929EE-EE15-4939-8711-1872549C311E Q38296151-10E11D3A-1F48-455B-B044-5305D056FA31 Q38544744-D11D9FE1-E908-4906-B8C4-86F29B9F8154 Q38650049-677088A6-8A52-49FC-8296-62911D28667F Q38690748-2647D9ED-F792-4FE4-A13B-BE26639E7BF2 Q38872130-36DFC3EE-7811-4C6F-AA9B-33F6CFB3C4B6 Q39066154-9BBB134E-5D22-47BC-8F76-81C37BF22F02 Q40052714-3199CF26-768A-4128-A443-A0ABF9D4D6DB

P2860

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

http://www.wikidata.org/entity/Q34299064

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@ast

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@en

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@nl

type

label

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@ast

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@en

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@nl

prefLabel

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@ast

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@en

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@nl

P1433

Q34299064-503D7D36-F8D3-40AC-9C43-5D417038D905

P1476

Q34299064-3719E42C-FC8F-41C7-8449-CD6A7377A01C

P2093

Q34299064-605B2E9D-4F25-4318-B77B-3DC2D4E2F88E

Q34299064-7F7481AB-22C1-4E1A-B96E-76645FB18233

Q34299064-84618CCA-B850-4387-BD7F-8BA5791053B2

Q34299064-A1EA4FA6-A886-4E70-AF1C-CDCE28E72314

Q34299064-D0065F52-944B-4A5F-9223-170515A1D10E

P2860

Q34299064-07B773B3-D722-4492-B9FB-46FF78D03884

Q34299064-24B16F87-D157-4EA9-B7EC-D933A96FDC87

Q34299064-39A01E25-A7A3-441D-BFCC-610A17E82C8E

Q34299064-41365CF3-6A22-4E6A-8823-8B8958C18269

Q34299064-41F29210-A854-4FDC-A6D8-49DB1A0A8B61

Q34299064-4E9A5294-4D20-4810-9D57-FF331B3B4BA9

Q34299064-6785EF73-6304-4F7A-B2F7-09D15356C925

Q34299064-692935CD-B628-4A76-BD7F-8013D2F9CAFF

Q34299064-8DBC0D34-3F5C-4623-AFBE-B2BA98B149DC

Q34299064-932D4729-15A9-487F-A739-D8EEF9F3BB8F

P304

Q34299064-300D4C74-EC92-4B2B-BB85-B1CF73783238

P31

Q34299064-52F162EC-CB85-4B5B-8C71-46E776BC6C3C

P356

Q34299064-BF4C4174-CD16-4539-9437-C1CF5E70133F

P407

Q34299064-433DC17A-687E-4817-AEBE-3859B1624D1A

P433

Q34299064-0937A8F2-E62A-4136-A90D-E4435EE8BF15

P478

Q34299064-8556F3E2-C61B-407F-AC42-008733F6B373

P50

Q34299064-7975074A-E3AA-4855-942A-76B7BE2B63C6

P577

Q34299064-0D6664EE-5558-497A-BF51-93C85E98DB27

P698

Q34299064-91ADE955-3FA9-47C2-BDF5-21704AAF1CE0

P932

Q34299064-D7B142B0-706F-4D35-AE1B-FCF4DF383362

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Impact of MIC range for Pseudo ...... inetic/pharmacodynamic target.

@en

P2093

A J Lepak

http://www.w3.org/2001/XMLSchema#string

A Reda

http://www.w3.org/2001/XMLSchema#string

J Van Hecker

http://www.w3.org/2001/XMLSchema#string

K Marchillo

http://www.w3.org/2001/XMLSchema#string

W A Craig

http://www.w3.org/2001/XMLSchema#string

P2860

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Animal model pharmacokinetics and pharmacodynamics: a critical review.

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

P304

6311-6314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.03572-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25092700

http://www.w3.org/2001/XMLSchema#string

P932

4187960

http://www.w3.org/2001/XMLSchema#string